Vaccine composition for preventing or treating brucellosis comprising attenuated Salmonella mutant as effective component

• Main Authors: KIM, WON KYONG, MOON, JA YOUNG, HUR, JIN
• Format: Patent
• Language: English; Korean
• Published: 22.05.2017
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; VINEGAR; WINE

The present invention relates to a vaccine composition for preventing and treating brucellosis comprising an attenuated salmonella mutant as an active ingredient. According to the present invention, attenuated Salmonella typhimurium is transformed by a vector developed to increase secretion of BSCP31, Omp31 or SOD antibody derived from Brucella abortus. In a mouse vaccinated with a mixture of a transgenic attenuated salmonella mutant, not only humoral and cell-mediated immune response to the antibody but also resistance to toxicity of Brucella abortus were exhibited. Accordingly, the mutant of the present invention is expected to be advantageously used as a vaccine for preventing and treating brucellosis which can be injected in a safe, economic, and convenient manner. 본 발명은 약독화된 살모넬라 변이주를 유효성분으로 포함하는 브루셀라증의 예방 또는 치료용 백신 조성물에 관한 것이다. 본 발명은 브루셀라 아보투스 유래 BSCP31, Omp31 또는 SOD 항원의 분비를 증가시키도록 개발된 벡터로 약독화된 살모넬라균(Typhimurium)을 형질전환시키고 상기 형질전환된 약독화된 살모넬라 변이주 혼합물을 접종시킨 마우스에서 항원에 대한 체액성 및 세포 매개 면역 반응뿐 아니라 브루셀라 아보투스 독성에 대하여 효과적으로 저항성을 보임을 확인하였다. 따라서, 본 발명의 변이주는 안전하고 경제적이며 간편하게 접종할 수 있는 브루셀라증 예방 및 치료용 백신으로 유용하게 사용될 것으로 기대된다.